Exchange & Returns Information
Review Details
(5)
| Drug Type | Original |
|---|---|
| Active Ingredient | BOSUTINIB |
| Strength | 100MG |
| Manufacturer | PFIZER |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 112 TABLETS | $ 4.62 | $ 517.00 |
$ 439.45
Apply ZARVY26 (-15%)
You save $ 77.55
|
||
| 2 BOXES - 224 TABLETS | $ 4.61 | $ 1,032.00 |
$ 877.20
Apply ZARVY26 (-15%)
You save $ 154.80
|
||
| ★ Best Value 3 BOXES - 336 TABLETS | $ 4.60 | $ 1,547.00 |
$ 1,314.95
Apply ZARVY26 (-15%)
You save $ 232.05
|
Reference information will be available soon.
Bosulif 100 is an oral tyrosine kinase inhibitor (TKI) containing bosutinib, specifically developed for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It is especially effective in patients who are resistant or intolerant to previous TKIs such as Imatinib, Dasatinib, or Nilotinib. Bosutinib inhibits both BCR-ABL and SRC family kinases, offering an alternative therapeutic strategy in advanced or high-risk disease stages. Recent clinical data have supported its use as a frontline treatment in select newly diagnosed cases.
- AntiCancer Drugs > Chronic Myeloid Leukemia (Ph+ CML) Indicated for patients who have developed resistance or intolerance to prior tyrosine kinase inhibitor therapy. It demonstrates a significant major molecular response (MMR), including in cases with BCR-ABL mutations (except T315I). > Newly Diagnosed CML Approved in some regions as a first-line therapy based on progression-free survival (PFS) and long-term tolerability. Particularly effective against a wide range of BCR-ABL mutations. > Accelerated Phase & Blast Crisis CML Used in patients with advanced-phase or blast crisis CML to suppress disease progression and as part of multi-line salvage protocols.
Bosutinib is a dual-action TKI that targets both BCR-ABL and SRC family kinases. Its potency against most BCR-ABL mutants—excluding T315I—makes it suitable for resistant CML cases. By suppressing disease progression in accelerated or blast phases, Bosutinib helps delay transformation to more aggressive stages. It has demonstrated durable responses and a manageable safety profile, particularly in long-term therapy.
Usual Adult Dose for Chronic Myelogenous Leukemia: - For newly diagnosed chronic phase (CP) Ph+ CML: 400 mg orally once daily with food Continue treatment until disease progression or intolerance - For chronic, accelerated, or blast phase Ph+ CML with resistance/intolerance: 500 mg orally once daily with food Continue until progression or unacceptable toxicity Additional Notes: - Take with food to enhance absorption and reduce gastrointestinal discomfort. - If a dose is missed by more than 12 hours, skip the missed dose and resume the regular schedule the following day. - No dose adjustment needed for mild to moderate renal impairment, but caution is advised in severe hepatic dysfunction.
Store below 30°C in a dry place, away from moisture and direct light. Keep in the original container and out of reach of children.
Common adverse effects include diarrhea, nausea, vomiting, abdominal pain, and elevated liver enzymes. Hematologic side effects such as thrombocytopenia, anemia, and neutropenia may occur. Long-term use may lead to hepatotoxicity or cardiovascular effects, requiring periodic monitoring of liver function tests and ECG.
For my CML treatment, I need a source for Bosulif that is 100% reliable. This pharmacy has been flawless month after month.
Bosulif is essential for me, and this site provides it reliably and discreetly. I'm a very grateful customer.
สั่งยา Bosulif สำหรับการรักษาของผม บริการเป็นมืออาชีพมาก และจัดส่งมาไทยได้รวดเร็วทันใจครับ
Managing my daily medication is simpler thanks to their easy re-ordering system. A very user-friendly website.
私のCML治療に不可欠なボスリフを、ここで確実に入手できるのは大きな安心です。サービスも迅速でプロフェッショナルです。
No combo deals available at the moment.
